Clinical trials: Pharmacogenomics
Colorectal Cancer
Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic
Pharmacogenomics (PGx) studies the interactions between an individuals genes and medications. PGx testing identifies genes within an individual that may affect treatment, efficacy, and toxicity of drugs.
- Trial name
- CRCPGx (NCT03187184)
- Testing
- OneOme RightMed®
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Essentia Health
Hypertension
Pharmacogenomic Evaluation of Antihypertensive Responses 2
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging.
- Trial name
- PEAR2 (NCT01203852)
- Testing
- Metoprolol, Chlorthalidone
- Where
- 3 sites in United States
- Volunteers
- 839 people
- Sponsor
- University of Florida
Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate
PGx Medication Safety Reviews of Persons With IDD
The purpose of this study is to assess the feasibility of a comprehensive medication review and PGx initiative as part of the care process for individuals in the care of CP Unlimited.
- Conditions
- Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate, Developmental Disability
- Trial name
- NCT07092852
- Testing
- Cheek swab for PGx testing, Medication safety review
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- GalenusRx, Inc.
Atherothrombosis
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
- Trial name
- PARes-II (NCT01894555)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Depression
Clinical Pharmacogenomics of Antidepressant Response
The purpose of this study is to understand how genetic polymorphisms influence the efficacy and side effect profiles of Paroxetine and Escitalopram for major depression treatment.
- Trial name
- NCT00384020
- Testing
- Paroxetine (Seroxat), Escitalopram (Lexapro)
- Where
- 4 sites in Taiwan
- Volunteers
- 402 people
- Sponsor
- National Health Research Institutes, Taiwan
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd
Type 2 Diabetes
Pharmacogenomics of Thiazolidinediones
The purpose of this study is to determine predictors of response to pioglitazone, an anti-diabetic medication. The investigators know from randomized clinical trials that some 30% of patients do not respond to this type of…
- Trial name
- PPAR (NCT01135394)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Epilepsy
Exploring the Effects of Genetic Variants and Inflammation on Vitamins Supplementation Treatment Outcomes in Epilepsy
The management of patients with epilepsy is focused on controlling seizures, avoiding treatment side effects, and restoring quality of life.
- Trial name
- NCT04488172
- Testing
- Multi-vitamin supplementation
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Cheng-Kung University Hospital
Hematopoietic Cell Transplantation, Oncology
Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the only curative treatment modality for many hematologic malignancies. Morbidity and mortality rates have declined drastically over the years, secondary to improvements in both…
- Trial name
- IMPPACT (NCT04727827)
- Testing
- Pharmacogenomic-guided supportive care
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Kidney Transplant Rejection, Kidney Transplant; Complications
Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore
The investigators hypothesise that the adaptation of CYP3A5 genotype-based Tacrolimus (FK) dosing will lead to earlier FK target achievement and consequently, better clinical outcome after kidney transplantation (RTx).
- Trial name
- NCT04825262
- Testing
- Tacrolimus
- Where
- Singapore
- Volunteers
- 74 people
- Sponsor
- Singapore General Hospital
Critical Illness
Clinical Trial on Individual Characteristics Affecting Pain Drug Therapy in Neonates
Children differ from adults with respect to growth and development but also immaturity of various pharmacological mechanisms. Dosing schemes in children are usually derived in an empirical manner from clinical trials in adult…
- Trial name
- NeoPopGen (NCT02426463)
- Testing
- propofol, oxycodone
- Where
- Finland
- Volunteers
- 80 people
- Sponsor
- Turku University Hospital
Pain
Pharmacokinetics of Oral Morphine and Pharmacogenomics of CYP2D6 and UGT2B7, in an Urban Pediatric Population Presenting for Elective Surgery
The purpose of this study is to identify and collect samples from children who have taken a single oral dose of the pain medication morphine, and to determine the genetic differences in the way children metabolize (break down in…
- Trial name
- NCT01071499
- Testing
- Morphine
- Where
- Canada
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Breast Neoplasms
Study to Evaluate Markers of Response in Locally Advanced Breast Cancer
The purpose of this study is to compare the association between image and certain molecular markers with complete response in patients with locally advanced breast cancer, treated with neoadjuvant chemotherapy composed of…
- Trial name
- IMAGING (NCT01338753)
- Testing
- Bevacizumab, docetaxel and doxorubicin followed by surgery
- Where
- 11 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Arthroplasty, Replacement, Knee, Pain, Postoperative
Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: a Pilot Study
The objective of this study is to see how pain management and its outcomes are effected when pharmacogenomic testing is used to determine patient specific pain medication and dosing.
- Trial name
- NCT02711592
- Testing
- Genetic Panel for Analgesics
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- TriHealth Inc.
Urine Toxicology
Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA
The objective of this study is to evaluate the impact of pharmacogenomic aspects of drug metabolism on the measurement of drug and drug metabolites on urine drug testing (UDT).
- Trial name
- UTOPIA (NCT02096172)
- Sponsor
- Renaissance RX
Pharmacogenomics and Cardiovascular Events
Pharmacogenomics and Effective Treatment With Clopidogrel
The aim of this biospecimen repository is to evaluate an individual's genotype, identify the variances, and understand how they relate to treatment with clopidogrel.
- Trial name
- NCT01611545
- Testing
- Pharmacogenomics
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Pediatric Disorder, Genetic Predisposition
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this…
- Conditions
- Pediatric Disorder, Genetic Predisposition, Dystonia, Secondary, Dystonia
- Trial name
- TRIKE2 (NCT06554288)
- Testing
- Trihexyphenidyl
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Mercy Hospital Kansas City
Depression, Adverse Reaction to Drug
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.
- Trial name
- NCT00817375
- Testing
- SSRI treated group, non-SSRI treated group
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Rheumatoid Arthritis
Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study
The purpose of this study is to obtain blood samples from up to 14 participants who previously received namilumab in the previous study M1-1188-002-EM (PRIORA, [NCT01317797]) to correlate genetic markers with clinical outcomes.
- Trial name
- NCT02528786
- Testing
- No Intervention
- Volunteers
- 8 people
- Sponsor
- Takeda
Behavioral Activation, Major Depressive Disorder
Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation
The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder…
- Conditions
- Behavioral Activation, Major Depressive Disorder, Anxiety Disorders, Antidepressant Drug Adverse Reaction
- Trial name
- PGx-SImBA (NCT06763081)
- Testing
- Not applicable- observational study
- Where
- 2 sites in Canada
- Volunteers
- 160 people
- Sponsor
- University of Manitoba